John Roderick ten Bosch, serving as Senior Vice President of Laboratory Operations for BillionToOne, Inc. (NASDAQ:BLLN), completed a divestment of 1,416 shares of the company's Class A Common Stock on June 29, 2026. The aggregate value of the transaction reached $169,920, with each share transacted at a price of $120.00. Subsequent market activity has pushed the stock price to $122.33, indicating a notable 11% gain over the preceding week.
Post-transaction, Mr. ten Bosch maintains a direct holding of 33,552 shares of BillionToOne Class A Common Stock. The sale was executed in accordance with a Rule 10b5-1 trading plan, which was originally adopted by Mr. ten Bosch on March 6, 2026. According to InvestingPro analysis, the stock currently exhibits characteristics of being overvalued relative to its Fair Value. Investors seeking comprehensive analysis may access the company's Pro Research Report, which is available for BLLN and over 1,400 other US equities.
In parallel developments, BillionToOne Inc. disclosed strong financial performance for the first quarter of 2026. Earnings per share reached $0.34, exceeding market expectations. The company's revenue for the quarter climbed to $108.4 million, marking an 84% increase compared to the previous year. These figures underscore significant growth in both revenue and profitability for the company.
Additionally, Guggenheim has increased its price target for BillionToOne shares from $100 to $120, while maintaining a Buy rating. This adjustment follows discussions with company management regarding new private payor contracting wins and improvements in the company's reimbursement position. During the company's annual meeting, shareholders elected Oguzhan Atay and Akshay Rai as Class I directors to serve until the 2029 annual meeting. These developments reflect recent progress and strategic decisions impacting BillionToOne.